Our results also suggest that urinary Vtn can be a potential non-invasive biomarker for kidney fibrosis and targeting Vtn/integrin β5/Src signaling could pave a new avenue for treating fibrotic CKD. This evidence concerns the gene VTN and chronic kidney disease.